TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04513886

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG) using the single incision technique, with and without suturing the palate
Description: A SCTG was harvested using the single incision technique described by Hürzeler \& Weng. The palatal incisions were standardized to extend between the area between mesial of the canine and mesial of the first molar.In the Suture Group sites a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate. In the no Suture Group sites, no suture was performed. In both groups, a CHS was placed after removing the graft to achieve the haemostasis of the palate and subsequent compressed with gauze soaked in saline for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG) using the single incision technique, with and without suturing the palate
Description: A SCTG was harvested using the single incision technique described by Hürzeler \& Weng. The palatal incisions were standardized to extend between the area between mesial of the canine and mesial of the first molar.In the Suture Group sites a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate. In the no Suture Group sites, no suture was performed. In both groups, a CHS was placed after removing the graft to achieve the haemostasis of the palate and subsequent compressed with gauze soaked in saline for 5 minutes.
Study: NCT03670043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psyllium powder
Description: To evaluate whether Psyllium will alleviate diarrhea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Extended Release Oral Tablet
Description: Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin
Study: NCT01732796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 24 weeks of active RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Faldaprevir)
Description: 16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 24 weeks of active RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 24 weeks of BI 207127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Faldaprevir)
Description: 24 weeks of BI 201335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 16 weeks BI 207127 followed by 8 weeks placebo to BI 207127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir (BI 201335)
Description: 24 weeks of 201335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 24 weeks of BI 207127
Study: NCT00771823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: * Placebo twice daily for the first 14 days of the study.~* Maraviroc 300 mg twice daily for the last 14 days of the study.
Study: NCT02667873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-801
Description: SL-801 is a small molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
Study: NCT02887235

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Delivered, Medically Tailored Meals (HDTM)
Study: NCT04157920

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Aortic Valve Implantation with ACURATE NEO/TF
Description: Transcatheter implantation of the heart valve device ACURATE neo/TF in patients suffering from severe aortic stenosis and are candidates for this operation

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcatheter Aortic Valve Implantation with Medtronic CoreValve /Evolut R/Pro
Description: Transcatheter implantation of the heart valve device Medtronic Evolut R/Pro in patients suffering from severe aortic stenosis and are candidates for this operation
Study: NCT04347070

Intervention type: OTHER
Intervention: Phsyiotherapy
Description: To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time
Study: NCT01788657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard internet-based cognitive behavior therapy
Description: Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed internet-based cognitive behavior therapy
Description: Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
Study: NCT04307160

Intervention type: PROCEDURE
Intervention: Bilateral lateral rectus recession
Description: All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed

Intervention type: PROCEDURE
Intervention: Bilateral lateral rectus recession
Description: All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed
Study: NCT01436136

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
Study: NCT01358890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low carbohydrate diet
Description: Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calories restricted diet
Description: Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
Study: NCT00454857

Intervention type: OTHER
Intervention: Retrospective Chart Review
Description: Retrospective chart review for up to 36 months of enrollment date.

Intervention type: OTHER
Intervention: Patient-reported Outcome Questionnaires
Description: Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).

Intervention type: OTHER
Intervention: Physician Survey
Description: Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
Study: NCT02483559

Intervention type: OTHER
Group type: OTHER
Intervention: Amber Lenses
Description: Glasses fitted with amber lenses that block the blue spectrum of light (\~470 nm) to be worn prior to desired sleep onset time.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Lenses
Description: Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
Study: NCT01835925

Intervention type: GENETIC
Intervention: Tissue specimen
Study: NCT03991000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Intravenous iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline application according to dosing rules of iron.
Study: NCT02197338

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bile Duct Cannulation
Description: Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bile Duct Cannulation
Description: Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bile Duct Cannulation
Description: Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bile Duct Cannulation
Description: Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
Study: NCT01299376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L50/H12.5/A5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L50/H12.5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to L50/H12.5/A5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to L50/H12.5
Study: NCT00240981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical testosterone gel 1% (active formulation)
Description: Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical gel (placebo formulation)
Description: Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
Study: NCT00766090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: Inhaled Corticosteroid
Study: NCT02428543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib and Cytarabine
Description: Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
Study: NCT03968107

Intervention type: OTHER
Intervention: Reference ultrasound examination
Description: Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
Study: NCT00821938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LV dp/dt pressure measurement
Description: Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LV dp/dt pressure measurement
Description: Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
Study: NCT02164175

Intervention type: DEVICE
Intervention: HeRO Graft implant for dialysis access
Description: End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
Study: NCT03199664

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: NB-UVB given twice weekly for 6 months

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB & Tacrolimus 0.03%
Description: NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
Study: NCT03920553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Topical application of hyaluronic acid following Laser assisted frenectomy
Study: NCT01025596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: 4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
Study: NCT02700568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
Study: NCT03244514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Implementation of the cardiovascular AKI bundle (see arm description)
Study: NCT00356889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally, 150 mg, once daily.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV, 5mg/kg on days 1 and 15 every cycle
Study: NCT02247960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Study: NCT00814671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine 450
Description: rifapentine 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine 600
Description: rifapentine 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: rifampin 600 mg
Study: NCT04645043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US_Eso
Description: After applying ultrasound guided esophageal pressure, the peak inspiratory pressure increased from 10cmH2O to 24cmH2O (increased by 2 cmH2O) during mask ventilation.
Study: NCT01639768

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUBLIVAC FIX Birch
Description: Comparison of different dosages to placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Birch
Description: Comparison of different dosages to placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Birch
Description: Comparison of different dosages to placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Birch
Description: Comparison of different dosages to placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Birch
Description: Comparison of different dosages to placebo
Study: NCT02529007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo-cuff
Description: Colonoscopy performed with endo-cuff attached to the colonoscope

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy without end-cuff
Study: NCT00813332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar(rh recombinant endostatin) plus Docetaxel
Description: 7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Docetaxel
Description: Placebo plus Docetaxel
Study: NCT03755791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Supplied as 20-mg tablets; administered orally daily at 40 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Cabozantinib
Description: Supplied as 60-mg tablets; administered orally once daily at 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Supplied as 200-mg tablets; administered orally twice daily at 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Supplied as 1200 mg/20 mL (60 mg/mL) in sing-dose vials; administered as an IV infusion once every 3 weeks (q3w).
Study: NCT04521036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma as Therapy for Covid-19 patients
Description: Patients in the treatment group will receive 500 ml from COVID-19 recovered donors
Study: NCT01678482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light based device for treatment of acne
Study: NCT02794467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
Study: NCT03564951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation
Description: ablation of Atrial fibrillation using spatio-temporal dispersion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Description: ablation of concordance zones using isochrone and voltage maps
Study: NCT04183283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT04654520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug therapy concurrent radiotherapy for primary tumor omitted CTV
Description: Thoracic intensity modulated radiotherapy for primary tumor omitted CTV+Chemotherapy or Targeted drug therapy
Study: NCT04143360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Closed Drainage Device
Description: For the first group, a new closed drainage device was adopted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional closed drainage device
Description: For group 2, conventional closed drainage device was used.
Study: NCT00861913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03851003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial suturing
Description: Suturing will include endometrium during cesarean incision repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non- endometrial suturing
Description: Suturing will not include endometrium during cesarean incision repair

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal ultrasonography
Description: All women will be invited six month post operation for vaginal sonographic evaluation of the uterine scar

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal ultrasonography
Description: All women will be invited six month post operation for vaginal sonographic evaluation of the uterine scar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: All women will be invited six month post operation for filling questionnaire concerning possibility of uterine scar defect ( spotting, pelvic pain, fertility abnormalities )

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: All women will be invited six month post operation for filling questionnaire concerning possibility of uterine scar defect ( spotting, pelvic pain, fertility abnormalities )
Study: NCT00517322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: ramipril 2.5- 5 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan
Description: irbesartan 150-300 mg once daily
Study: NCT03625687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Description: 8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
Study: NCT02839057

Intervention type: PROCEDURE
Intervention: Non-surgical treatment
Description: Cervical collar immobilisation for 12 weeks.

Intervention type: PROCEDURE
Intervention: Surgical treatment
Description: Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
Study: NCT03945357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/ clindamycin
Description: Comparison of saline solution rinse vs antibiotic rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Comparison of saline solution rinse vs antibiotic rinse
Study: NCT01543828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: delivered via single-dose dry-powder inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: delivered via single-dose dry-powder inhaler
Study: NCT03429881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stripping versus laser CO2
Description: Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stripping versus laser CO2
Description: Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.